Diabetes Insipidus

Diabetes insipidus (DI) is a rare endocrine disorder characterized by the inability to concentrate urine, leading to polyuria (excessive urine production) and polydipsia (compensatory excessive water intake). The condition arises from either a deficiency of antidiuretic hormone (ADH, also known as arginine vasopressin, AVP) production or secretion (central diabetes insipidus, CDI) or from renal resistance to the actions of ADH (nephrogenic diabetes insipidus, NDI). In veterinary medicine, DI is most commonly diagnosed in dogs and cats, though it can occur in other species. The disease is classified into two main types: central (neurogenic) and nephrogenic. Central DI results from lesions in the hypothalamus or pituitary gland that impair synthesis or release of ADH, while nephrogenic DI results from impaired renal response to ADH, often due to tubular dysfunction or receptor defects. A third, less common form is gestational DI, which occurs during pregnancy due to increased metabolism of ADH by the placenta, but this is rarely reported in veterinary patients. The hallmark of DI is the excretion of large volumes of dilute urine (urine specific gravity typically <1.010) despite normal or elevated plasma osmolality, and the condition must be differentiated from other causes of polyuria and polydipsia (PU/PD), such as diabetes mellitus, chronic kidney disease, hyperadrenocorticism, and psychogenic polydipsia. Accurate diagnosis and differentiation between central and nephrogenic forms are critical for appropriate management and prognosis.

The etiology of diabetes insipidus varies depending on the type. Central diabetes insipidus (CDI) is caused by any condition that disrupts the synthesis, transport, or release of ADH from the hypothalamus or posterior pituitary. Common causes include: 1) Neoplasia: primary brain tumors such as craniopharyngioma, pituitary adenoma, or metastatic tumors (e.g., lymphoma, mammary carcinoma) that compress or infiltrate the hypothalamic-neurohypophyseal axis. 2) Trauma: head trauma, particularly fractures of the base of the skull, or iatrogenic injury during intracranial surgery. 3) Inflammatory or infectious diseases: granulomatous meningoencephalitis, infectious encephalitis (e.g., canine distemper virus, toxoplasmosis, fungal infections such as cryptococcosis), or immune-mediated hypophysitis. 4) Congenital defects: rare congenital malformations of the hypothalamus or pituitary, sometimes associated with other midline defects. 5) Idiopathic: many cases are classified as idiopathic when no underlying cause is identified. Nephrogenic diabetes insipidus (NDI) results from renal resistance to ADH, which can be due to: 1) Congenital defects: X-linked recessive mutations in the V2 receptor gene or autosomal recessive mutations in the aquaporin-2 water channel gene, though these are rare in veterinary patients. 2) Acquired causes: chronic kidney disease, particularly interstitial nephritis, pyelonephritis, hyperadrenocorticism (Cushing's syndrome), hypercalcemia, hypokalemia, hepatic insufficiency, and certain drugs such as lithium (rarely used in veterinary medicine) or demethylchlortetracycline. 3) Endocrine disorders: hyperadrenocorticism and hypoadrenocorticism can interfere with renal concentrating ability. 4) Metabolic disturbances: hypercalcemia and hypokalemia impair the renal response to ADH. 5) Pyometra in dogs, due to endotoxin-induced renal tubular dysfunction. 6) Amyloidosis, particularly in cats. In many cases of NDI, the underlying cause is reversible if the primary condition is treated.

Diabetes insipidus is an uncommon condition in veterinary medicine, with no specific breed or sex predilection reported for the central form, although it may be more common in middle-aged to older animals due to the higher incidence of neoplasia. In dogs, certain breeds may be predisposed to congenital NDI, such as the Siberian Husky, where an X-linked form has been documented. Central DI can occur in any breed, but brachycephalic breeds may be at higher risk for traumatic brain injury leading to DI. Cats are less commonly affected than dogs. There is no clear geographic or seasonal pattern. The incidence of DI is difficult to estimate due to its rarity, but it is more frequently diagnosed in dogs than cats. In dogs, the median age at diagnosis is around 5-7 years, but it can occur at any age. No sex predilection is consistently reported, though some studies suggest a slight female predominance for central DI. Congenital NDI is typically diagnosed in young animals, often before one year of age. Acquired NDI is more common in older animals with underlying diseases such as chronic kidney disease or hyperadrenocorticism.

The pathophysiology of diabetes insipidus revolves around the disruption of water homeostasis. In normal animals, ADH is synthesized in the supraoptic and paraventricular nuclei of the hypothalamus and transported via axons to the posterior pituitary, where it is stored and released in response to increased plasma osmolality or decreased blood volume. ADH acts on V2 receptors in the basolateral membrane of renal collecting duct principal cells, activating the cAMP pathway, which leads to the insertion of aquaporin-2 water channels into the apical membrane, allowing water reabsorption and urine concentration. In central DI, there is a deficiency of ADH, either due to destruction of the hypothalamic nuclei or damage to the pituitary stalk or posterior pituitary. This results in the inability to concentrate urine, leading to the excretion of large volumes of dilute urine. The loss of free water triggers a compensatory increase in thirst, leading to polydipsia. If water intake is inadequate, severe hypernatremia and hyperosmolality can develop, leading to neurological signs. In nephrogenic DI, ADH is produced normally, but the renal tubules are unable to respond to it. This can be due to defects in the V2 receptor or aquaporin-2 channels (congenital) or due to acquired conditions that interfere with the intracellular signaling cascade or the osmotic gradient in the renal medulla. For example, hypercalcemia and hypokalemia impair the action of ADH on the collecting duct, and chronic kidney disease reduces the ability to generate a hypertonic medullary interstitium. In both forms, the primary defect leads to the production of large volumes of hypotonic urine, with urine specific gravity typically less than 1.010. The severity of clinical signs depends on the degree of ADH deficiency or resistance and the animal's ability to compensate by increasing water intake.

Predisposing factors for diabetes insipidus include: 1) Age: Central DI can occur at any age, but congenital forms are more likely in young animals. Acquired NDI is more common in older animals due to underlying diseases. 2) Breed: Certain breeds, such as Siberian Huskies, are predisposed to congenital NDI. 3) Sex: X-linked congenital NDI is more common in males. 4) Concurrent diseases: Hyperadrenocorticism, chronic kidney disease, hypercalcemia, hypokalemia, pyometra, and hepatic insufficiency can predispose to NDI. 5) Trauma: Head trauma is a risk factor for central DI. 6) Neoplasia: Pituitary or hypothalamic tumors are significant risk factors for central DI. 7) Medications: Certain drugs, such as glucocorticoids (in the context of hyperadrenocorticism) or diuretics, can impair urine concentrating ability. 8) Genetic mutations: Mutations in the V2 receptor or aquaporin-2 genes are rare but can predispose to congenital NDI. 9) Environmental factors: Access to water is crucial; animals with limited water intake may develop severe hypernatremia.

The primary clinical signs of diabetes insipidus are polyuria and polydipsia. Owners often report that the animal drinks excessively and urinates large volumes, sometimes leading to house soiling or nocturia. The urine is typically very dilute, with a specific gravity usually less than 1.010. In severe cases, animals may develop dehydration, hypernatremia, and neurological signs such as lethargy, depression, ataxia, seizures, or coma if water intake is insufficient. However, most animals with DI are able to maintain hydration by drinking enough water, so clinical signs are often limited to PU/PD. In central DI, the onset may be acute, especially after trauma or surgery, or gradual if due to a slow-growing tumor. In nephrogenic DI, the onset is often insidious, and signs may be less severe. Other signs may include weight loss, poor coat quality, and, in cases of underlying neoplasia, neurological deficits such as visual impairment, circling, or behavioral changes. Physical examination is often unremarkable except for signs of dehydration if water is restricted. In animals with concurrent hyperadrenocorticism, signs such as pot-bellied appearance, alopecia, and muscle weakness may be present. In cases of pyometra, vaginal discharge and systemic signs may be noted.

Differential diagnoses for polyuria and polydipsia (PU/PD) include: 1) Diabetes mellitus: Characterized by hyperglycemia and glucosuria; serum glucose and urinalysis will confirm. 2) Chronic kidney disease (CKD): Often associated with azotemia, isosthenuria (urine specific gravity 1.008-1.012), and other signs such as weight loss and poor appetite. 3) Hyperadrenocorticism (Cushing's syndrome): May show elevated cortisol levels, abnormal ACTH stimulation test, and characteristic physical findings. 4) Psychogenic polydipsia: Primary excessive water intake leading to dilute urine; diagnosis is made by excluding other causes and observing normal urine concentration after water restriction. 5) Pyometra in intact females: May have vaginal discharge, systemic signs, and leukocytosis; imaging and cytology can help. 6) Hypercalcemia: Can cause NDI; serum calcium levels will be elevated. 7) Hypokalemia: Can impair urine concentrating ability; serum potassium levels will be low. 8) Hepatic insufficiency: May be associated with other signs such as jaundice, and liver function tests will be abnormal. 9) Acromegaly: Rare, but can cause insulin resistance and PU/PD. 10) Drug-induced: Glucocorticoids, diuretics, or other medications can cause PU/PD. 11) Pyelonephritis: May have fever, flank pain, and positive urine culture. 12) Renal amyloidosis: Especially in cats, may be associated with proteinuria and renal failure. 13) Diabetes insipidus: Both central and nephrogenic forms must be considered. The key differentiating feature is the response to water deprivation and exogenous ADH administration.

The diagnostic approach to diabetes insipidus involves a stepwise process: 1) Confirm polyuria and polydipsia: Document urine output (if possible) and water intake. 2) Perform a thorough history and physical examination. 3) Baseline laboratory tests: Complete blood count, serum biochemistry profile, urinalysis (including urine specific gravity), and urine culture if indicated. These tests help rule out common causes of PU/PD such as diabetes mellitus, CKD, hypercalcemia, hypokalemia, and pyometra. 4) If baseline tests are unremarkable, consider endocrine testing for hyperadrenocorticism (ACTH stimulation test or low-dose dexamethasone suppression test) if clinical signs suggest it. 5) If hyperadrenocorticism is ruled out, proceed to a water deprivation test. This test should be performed only in a hospital setting with careful monitoring. The animal is deprived of water for a period (usually 6-12 hours) while monitoring body weight, urine specific gravity, and plasma osmolality. The test is stopped if the animal loses more than 5% of body weight, becomes dehydrated, or if urine specific gravity rises above 1.030. In animals with DI, urine specific gravity remains low (<1.010) despite water deprivation, and plasma osmolality may rise. 6) After water deprivation, administer exogenous ADH (desmopressin, DDAVP) and monitor urine specific gravity. In central DI, urine specific gravity should increase by more than 50% within 2-4 hours. In nephrogenic DI, there is little or no response. 7) Alternatively, a desmopressin trial can be performed without water deprivation: administer DDAVP and monitor urine specific gravity over 24-48 hours. If urine specific gravity increases significantly, central DI is likely. 8) Advanced imaging (MRI or CT) of the brain may be indicated to identify underlying lesions in central DI, especially if neurological signs are present or if the animal is older. 9) In cases of suspected nephrogenic DI, further evaluation of renal function and underlying causes (e.g., hypercalcemia, hypokalemia, hyperadrenocorticism) is warranted.

In diabetes insipidus, routine laboratory findings are often unremarkable except for a low urine specific gravity (typically <1.010). Serum biochemistry may show mild hypernatremia if the animal is dehydrated, but most animals are euhydrated due to compensatory polydipsia. Complete blood count is usually normal. Urinalysis reveals dilute urine with no other abnormalities. In cases of nephrogenic DI due to underlying diseases, laboratory findings may reflect the primary condition: hypercalcemia (elevated total or ionized calcium), hypokalemia (low serum potassium), azotemia (elevated BUN and creatinine) in CKD, or elevated liver enzymes in hepatic insufficiency. In hyperadrenocorticism, there may be elevated alkaline phosphatase, cholesterol, and glucose. In pyometra, there may be leukocytosis and hyperglobulinemia. Specific tests for DI include: 1) Water deprivation test: During the test, urine specific gravity remains low, and plasma osmolality may increase. 2) Desmopressin response test: After administration of DDAVP, urine specific gravity increases significantly in central DI but not in nephrogenic DI. 3) Measurement of plasma ADH levels: This is rarely performed in clinical practice but can differentiate central (low ADH) from nephrogenic (normal or high ADH) DI. 4) Serum osmolality: May be normal or slightly elevated. 5) Urine osmolality: Typically low (<300 mOsm/kg). 6) In cases of suspected congenital NDI, genetic testing may be available for specific mutations.

Imaging plays a crucial role in the diagnosis of central diabetes insipidus, particularly in identifying underlying structural lesions. Magnetic resonance imaging (MRI) is the modality of choice for evaluating the hypothalamus and pituitary gland. In central DI, MRI may reveal a mass lesion (e.g., pituitary tumor, craniopharyngioma) or absence of the normal hyperintense signal of the posterior pituitary on T1-weighted images (the 'bright spot' is often absent). In cases of trauma, MRI may show hemorrhage or edema in the hypothalamic-pituitary region. Computed tomography (CT) can also be used, but MRI provides better soft tissue contrast. In nephrogenic DI, imaging of the kidneys may be indicated to assess for chronic kidney disease, pyelonephritis, or other renal abnormalities. Abdominal ultrasound can evaluate renal size, echogenicity, and structure. In cases of pyometra, ultrasound of the uterus may show fluid-filled distension. Thoracic radiographs may be indicated if metastatic disease is suspected. In all cases, imaging should be guided by clinical signs and laboratory findings.

Cytology and histopathology are not typically used for the diagnosis of diabetes insipidus itself, but they are valuable in identifying underlying causes. If a brain mass is identified on imaging, a biopsy may be performed for histopathological diagnosis. Pituitary tumors can be classified as adenomas, adenocarcinomas, or other neoplasms. Craniopharyngiomas are rare but can be diagnosed histologically. Inflammatory lesions may show lymphocytic infiltration, granulomatous inflammation, or infectious agents. In cases of nephrogenic DI due to renal disease, a renal biopsy may be performed to characterize the underlying pathology, such as interstitial nephritis, glomerulonephritis, or amyloidosis. Histopathology of the kidney can reveal tubular atrophy, fibrosis, or amyloid deposition. Cytology of cerebrospinal fluid (CSF) may be helpful if inflammatory or neoplastic disease is suspected; it may show increased protein and cell counts, or neoplastic cells. However, CSF analysis is not specific for DI.

The treatment of diabetes insipidus depends on the type and underlying cause. For central diabetes insipidus, the mainstay of therapy is desmopressin acetate (DDAVP), a synthetic analog of ADH. DDAVP is available as an oral tablet, oral solution, or injectable solution. The typical dose for dogs is 1-2 drops of the ophthalmic solution (0.01%) administered into the conjunctival sac or on the oral mucosa, or 0.1-0.2 mg orally every 8-12 hours. For cats, the dose is similar. Alternatively, injectable DDAVP (4 mcg/mL) can be given subcutaneously at a dose of 1-4 mcg per animal every 12-24 hours. The dose is titrated to achieve normal water intake and urine specific gravity (usually >1.015). Overdosing can lead to water intoxication and hyponatremia, so careful monitoring is required. If an underlying cause such as a brain tumor is identified, treatment may include surgery, radiation therapy, or chemotherapy, but these are often palliative. For nephrogenic diabetes insipidus, treatment focuses on addressing the underlying cause. If hypercalcemia or hypokalemia is present, correction of these electrolyte imbalances may restore renal concentrating ability. In cases of hyperadrenocorticism, treatment of the underlying endocrine disorder (e.g., trilostane or mitotane for pituitary-dependent hyperadrenocorticism) may improve PU/PD. For congenital NDI, treatment is challenging; thiazide diuretics (e.g., hydrochlorothiazide at 1-2 mg/kg PO q12h) in combination with a low-sodium diet may reduce urine output by decreasing extracellular fluid volume and increasing proximal tubular water reabsorption. Nonsteroidal anti-inflammatory drugs (NSAIDs) such as indomethacin (0.5-1 mg/kg PO q12h) have been used to reduce prostaglandin synthesis, which may enhance ADH action, but their use is limited due to potential side effects. In all cases, access to fresh water must be unlimited to prevent dehydration. Supportive care includes monitoring hydration status, body weight, and serum electrolytes.

The prognosis for diabetes insipidus depends on the underlying cause. For idiopathic central DI, the prognosis is generally good with appropriate desmopressin therapy, and animals can live a normal lifespan with proper management. However, if central DI is due to a progressive brain tumor, the prognosis is guarded to poor, depending on the tumor type and response to treatment. For nephrogenic DI, the prognosis depends on the reversibility of the underlying cause. If the cause is reversible (e.g., hypercalcemia, hypokalemia, drug-induced), the prognosis is good once the underlying condition is corrected. If the cause is irreversible (e.g., congenital NDI, end-stage chronic kidney disease), the prognosis is more guarded, and long-term management may be challenging. In congenital NDI, the prognosis is variable; some animals respond to thiazide diuretics and dietary modification, but others may develop chronic kidney disease over time. Overall, with proper management, many animals with DI can maintain a good quality of life.

Follow-up for diabetes insipidus involves regular monitoring of clinical signs, water intake, urine specific gravity, and serum electrolytes. Initially, after starting desmopressin therapy, animals should be re-evaluated within 1-2 weeks to assess response and adjust the dose. Once stabilized, re-checks every 3-6 months are recommended. During each visit, a thorough physical examination, body weight measurement, and urinalysis should be performed. Serum biochemistry, including electrolytes, should be checked periodically, especially if the animal is on desmopressin, to monitor for hyponatremia or other imbalances. If the underlying cause is a brain tumor, repeat imaging (MRI or CT) may be indicated every 6-12 months to assess tumor progression. For nephrogenic DI, monitoring of the underlying disease (e.g., renal function, calcium, potassium) is essential. Owners should be educated to monitor water intake and urine output at home and to report any changes. If the animal develops signs of dehydration, lethargy, or neurological abnormalities, immediate veterinary attention is required.

Pearls: 1) Always rule out common causes of PU/PD (diabetes mellitus, CKD, hyperadrenocorticism) before considering DI. 2) The water deprivation test is the gold standard for diagnosing DI, but it must be performed with extreme caution to avoid severe dehydration or hypernatremia. 3) Desmopressin is the treatment of choice for central DI; it is safe and effective, but dosing must be individualized. 4) In nephrogenic DI, treating the underlying cause is the primary goal; thiazide diuretics can be helpful in congenital cases. 5) Always ensure unlimited access to water in animals with DI to prevent hypernatremia. Pitfalls: 1) Failing to perform a water deprivation test correctly can lead to misdiagnosis; the test should be stopped if the animal loses >5% body weight or becomes dehydrated. 2) Overdosing desmopressin can cause water intoxication and hyponatremia, which can be life-threatening. 3) Assuming that a low urine specific gravity always indicates DI; it can also be seen in psychogenic polydipsia, which requires a different approach. 4) In nephrogenic DI, using desmopressin is ineffective and may lead to water retention if the animal is overhydrated. 5) Not investigating for underlying causes in older animals with central DI can miss a brain tumor, which may be treatable.

Based on Plumb's Veterinary Drug Handbook, the following drug protocols are recommended for diabetes insipidus: 1) Desmopressin acetate (DDAVP): For central DI, the oral tablet dose is 0.1-0.2 mg per dog or cat every 8-12 hours. The oral solution (0.01%) can be given at 1-2 drops into the conjunctival sac or on the oral mucosa every 12-24 hours. The injectable solution (4 mcg/mL) can be given subcutaneously at 1-4 mcg per animal every 12-24 hours. The dose should be titrated to achieve normal water intake and urine specific gravity >1.015. 2) Hydrochlorothiazide: For nephrogenic DI, the dose is 1-2 mg/kg orally every 12 hours. It is often used in combination with a low-sodium diet. 3) Indomethacin: May be used in nephrogenic DI at 0.5-1 mg/kg orally every 12 hours, but its use is limited due to potential gastrointestinal and renal side effects. 4) For underlying hyperadrenocorticism, trilostane (2-6 mg/kg orally every 24 hours) or mitotane (50 mg/kg orally daily for 7-10 days, then 50 mg/kg weekly) may be used. 5) For hypercalcemia, treatment includes intravenous fluids (0.9% NaCl), furosemide (1-2 mg/kg IV or PO every 8-12 hours), and glucocorticoids (e.g., prednisone 0.5-1 mg/kg PO every 12 hours) if indicated. 6) For hypokalemia, potassium supplementation (e.g., potassium gluconate 2-4 mEq/kg/day PO) is recommended. 7) For pyometra, surgical ovariohysterectomy is the treatment of choice, along with antibiotics and supportive care. All drug dosages should be adjusted based on renal and hepatic function, and animals should be monitored for adverse effects.

Evidence-based literature on diabetes insipidus in veterinary medicine is limited due to the rarity of the condition. However, several key studies and reviews provide guidance: 1) A study by Feldman and Nelson (2004) in 'Canine and Feline Endocrinology and Reproduction' provides a comprehensive review of DI, including diagnostic and therapeutic approaches. 2) A study by Aroch et al. (2005) described the use of desmopressin in dogs with central DI, showing good response and minimal side effects. 3) A study by Nichols (2001) evaluated the water deprivation test in dogs and cats, establishing protocols and safety guidelines. 4) A study by van Vonderen et al. (2004) investigated the use of desmopressin in cats with central DI, demonstrating efficacy. 5) For nephrogenic DI, a study by Lulich et al. (1997) reported the use of hydrochlorothiazide in dogs with congenital NDI, showing reduced urine output. 6) ACVIM consensus statements on PU/PD (e.g., by Behrend et al., 2013) provide algorithms for diagnosing DI and other causes. 7) A study by Grooters et al. (1998) described the MRI findings in dogs with central DI, highlighting the absence of the posterior pituitary bright spot. 8) A retrospective study by Henson et al. (2008) evaluated the prognosis of dogs with central DI due to pituitary tumors, showing that radiation therapy can improve survival. Overall, the evidence supports the use of desmopressin for central DI and the importance of identifying and treating underlying causes in nephrogenic DI.